Naproxen
- Generic Name
- Naproxen
- Brand Names
- Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14O3
- CAS Number
- 22204-53-1
- Unique Ingredient Identifier
- 57Y76R9ATQ
- Background
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
- Indication
Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskeletal inflammation and pain.
- Associated Conditions
- Acute Gouty Arthritis, Acute Migraine, Ankylosing Spondylitis (AS), Back pain, Bursitis, Extra-Articular Rheumatism, Fever, Flu caused by Influenza, Headache, Juvenile Idiopathic Arthritis (JIA), Menstrual Distress (Dysmenorrhea), Migraine, Muscle Spasms, Nasal Congestion, Osteoarthritis (OA), Pain, Post Traumatic Pain, Postoperative pain, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Seasonal Allergic Rhinitis, Sinusitis, Tendinitis, Toothache, Articular inflammation
- Associated Therapies
- -
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
- Conditions
- MigraineHeadache
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Registration Number
- NCT01390324
Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers
- Conditions
- Juvenile Idiopathic Arthritis
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01358383
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis
- Conditions
- Osteoarthritis, Knee
- Interventions
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01343303
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
- Conditions
- Migraine
- Interventions
- Drug: Sumatriptan/Naproxen SodiumDrug: Naproxen Sodium
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Cady, Roger, M.D.
- Target Recruit Count
- 40
- Registration Number
- NCT01300546
- Locations
- 🇺🇸
Newport Beach Clinical Research Assoc., Inc., Newport Beach, California, United States
🇺🇸Clinvest, Springfield, Missouri, United States
Acute Osteoarthritis Experimental Model Study.
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 53
- Registration Number
- NCT01231490
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Study of Naproxen Capsules to Treat Dental Pain
- First Posted Date
- 2010-10-27
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- Iroko Pharmaceuticals, LLC
- Target Recruit Count
- 254
- Registration Number
- NCT01229228
- Locations
- 🇺🇸
Premier Research Group Limited, Austin, Texas, United States
A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee
- Conditions
- Osteoarthritis of the Knee
- Interventions
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 322
- Registration Number
- NCT01207115
- Locations
- 🇺🇸
Site Reference ID/Investigator# 37222, Burbank, California, United States
🇺🇸Site Reference ID/Investigator# 37227, Milford, Connecticut, United States
🇺🇸Site Reference ID/Investigator# 37229, Boynton Beach, Florida, United States
The Effects of Three Oral Medications on Post-operative Pain Following Endodontic Treatment
- Conditions
- PulpitisPain Management
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Azad University of Medical Sciences
- Registration Number
- NCT01178203
To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee
- Conditions
- Osteoarthritis
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 169
- Registration Number
- NCT01160822
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Westlake Medical Research, Westlake Village, California, United States
🇺🇸San Diego Arthritis & Osteoporosis Medical Clinic, San Diego, California, United States
Phase I Study on Multiple Oral Dosing of CG100649
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- CrystalGenomics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01154790
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.